A Randomized, Double-blind, Multicenter Phase III Study of XNW5004 Tablets in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma
Clinical trial NCT06776952 · RECRUITING
Trial details
- NCT number
- NCT06776952
- Sponsor
- Evopoint Biosciences Inc.
- Status
- RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2025-04-10
- Primary completion
- 2028-01-01
- Enrollment
- 120
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.